Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Barlesi

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]M F Mosele, C B Westphalen, A Stenzinger, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?A Mavrikios, M Bortolot, C Le Péchoux, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2018
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesE E Vokes, N Ready, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2025
Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple InstitutionsM Aldea, L Zullo, V Levrat, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]M F Mosele, C B Westphalen, A Stenzinger, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2026
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?A Mavrikios, M Bortolot, C Le Péchoux, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2018
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesE E Vokes, N Ready, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2025
Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple InstitutionsM Aldea, L Zullo, V Levrat, et al.
Pageof 9